|
Report Date : |
02.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
BOZO RESEARCH CENTER INC |
|
|
|
|
Registered Office : |
36-7 Oyamacho Shibuyaku |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.08.2011 |
|
|
|
|
Date of Incorporation : |
February 1972 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Consigned mfg of pharmaceuticals, reagents, food additives, cosmetics |
|
|
|
|
No. of Employees : |
460 |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
-- |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Japan
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BOZO RESEARCH CENTER INC
REGD NAME: KK
Bozo Research Center
MAIN OFFICE: 36-7
Oyamacho Shibuyaku
Tel:
03-5453-8101 Fax: 03-5453-8109
E-Mail address: info@bozo.co.jp
Consigned mfg of
pharmaceuticals, reagents, food additives, cosmetics
Osaka, Shin-Osaka,
Shizuoka, Hakodate
Osaka, Shin-Osaka
(subcontracted)
KUMI YAMAUCHI,
PRES Hiroshi Yamauchi, v pres
Naomi Yamauchi,
dir Miho Yoshikawa, dir
Keiichiro
Yoshikawa, dir
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 5,400 M
PAYMENTS NO COMPLAINTS CAPITAL Yen 97 M
TREND SLOW WORTH Yen 97 M
STARTED 1972 EMPLOYES 460
CONSIGNED MFR OF PHARMACEUTICALS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject company was established
by Kumi Yamauchi, a graduate of medical college, in order to make most of her
experience in the subject line of business. This is a consigned mfr of pharmaceuticals,
reagents, food additives, cosmetics, agrochemicals, other. Clients include major pharmaceutical makers,
wholesalers, other.
The sales volume for Aug/2011 fiscal
term amounted to Yen 5,400 million, an 11% down from Yen 6,065 million in the
previous term. The recurring profit was
posted at Yen 212 million and the net profit at Yen 104 million, respectively,
compared with Yen 271 million recurring profit and Yen 208 million net profit,
respectively, a year ago.
For the current term ending Aug 2012
the recurring profit is projected at Yen 220 million and the net profit at yen
110 million, respectively, on a 3% rise in turnover, to Yen 5,550 million.
The financial situation is considered FAIR
and good for ORDINARY business engagements.
Date Registered: Feb
1972
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 780,000 shares
Issued: 195,000 shares
Sum: Yen 97.5 million
Major
shareholders (%): Kumi Yamauchi (51), Falma Inc (12), Hiroshi Yamauchi (10)
No. of shareholders: 7
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Consigned mfr of
pharmaceuticals, reagents, cosmetics, food additives, agrochemicals, other
(--100%)
Clients: [Mfrs,
wholesalers] Astellas Pharmaceuticals, Takeda Pharmaceutical Co, Hisamitsu
Pharmaceutical Co, Shionogi Pharmaceutical, Daiichi Sankyo Co Group, other
No. of accounts:
300
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Falma Co, Oriental Yeast Co, Japan Laboratory Animals Inc, Charles
River Laboratories Japan, Clea Japan Inc, Mediceo Corp, other
Payment
record: No Complaints
Location: Business area in
Tokyo. Office premises at the caption
address are owned and maintained satisfactorily.
Bank References:
Resona Bank
(Shibuya)
MUFG (H/O)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
31/08/2012 |
31/08/2011 |
31/08/2010 |
31/08/2009 |
|
|
Annual
Sales |
|
5,550 |
5,400 |
6,065 |
7,327 |
|
Recur.
Profit |
|
220 |
212 |
271 |
547 |
|
Net
Profit |
|
110 |
104 |
208 |
324 |
|
Total
Assets |
|
|
11,028 |
10,060 |
10,789 |
|
Current
Assets |
|
|
7,576 |
6,664 |
7,327 |
|
Current
Liabs |
|
|
6,128 |
5,306 |
6,078 |
|
Net
Worth |
|
|
1,989 |
1,905 |
1,731 |
|
Capital,
Paid-Up |
|
|
97 |
97 |
97 |
|
Div.P.Share(₯) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
2.78 |
-10.96 |
-17.22 |
4.39 |
|
|
Current Ratio |
|
.. |
123.63 |
125.59 |
120.55 |
|
N.Worth Ratio |
.. |
18.04 |
18.94 |
16.04 |
|
|
R.Profit/Sales |
|
3.96 |
3.93 |
4.47 |
7.47 |
|
N.Profit/Sales |
1.98 |
1.93 |
3.43 |
4.42 |
|
|
Return On Equity |
.. |
5.23 |
10.92 |
18.72 |
|
Notes: Forecast
(or estimated) figures for the 31/08/2012 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.92 |
|
|
1 |
Rs.86.03 |
|
Euro |
1 |
Rs.69.13 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.